CURESPONSE

Curesponse is on a Mission to Improve Cancer Treatment.

ISO 15189 Approved

cResponse™ combines rapid genomic sequencing with a functional test, enabling prioritization of different therapeutic options for patients with metastatic cancer.

The cResponse™ solution

cResponse™ combines a revolutionary 3-dimensional tissue culture system and rapid next generation sequencing to help you prioritize and choose the potential best treatment for your patients. Drugs are tested on the cResponse™ assay based on your recommendations and the result of a rapid genomic sequencing test, and then evaluated and prioritized for efficacy in our proprietary 3D system.

The cResponse™ advantage

It is well established that all tumors are different and will respond differently to anti- cancer drugs. Genomic sequencing provides a list of potential therapeutic options and the cResponse™ test actually evaluates them on your patient's tumor. The tumor microenvironment (TME), plays a central role in drug response and in many cases is a major factor in the development of resistance for cancer drugs. The cResponse™ platform preserves the tissue's 3D structure and maintains the TME (including vasculature and immune system), enabling assessment of tumor response of the tumor to drugs in laboratory conditions and prioritization of the drugs based on their potential effect.

The testing procedure



A fresh biopsy arrives at a regional cResponse™ service center. Part of the sample undergoes rapid genomic sequencing to identify tumor-specific genomic alterations that may be targeted by specific anti-cancer drugs. Added to those selected by the physician, they create a panel of therapies to be tested in the system. The biopsy is cut into thick sections which are placed in a proprietary assay culture matrix and tests the cancer's sensitivity to various drugs or novel drug combinations. cResponse's proprietary evaluation system and response algorithm then prioritizes the options according to demonstrated drug efficacy, providing results, usually within two weeks.

A Patient's cResponse™ Score

After evaluation in the cResponse™ system and proprietary algorithm, each drug is assigned a score of 0-100, with 100 reflecting a strong response of the tissue to this therapy and reflecting no response. The highest scoring drugs represent the most efficacious treatment on our proprietary assay. The cResponse™ score chart and images of patient tissue are included in the report.

The cResponse™ chart



Images of the patient tissue



Pathological evaluation of the slide:

Prior to analysis, the slides are stained with H&E and Ki67, and are then evaluated by a team of our in-house pathologists. The response of the tissue sections to drug or drug combination is analyzed by several parameters: viability, quality and proliferation of the cancer cells on the slide. The values are computed to generate a final score which represents the tissue response.

A list of the genes tested in our panel

286 amplicons covering hotspots of 57 actionable genes

ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, DDR2, DNMT3A, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MPL, MSH6, NOTCH1, NMP1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53 (w hole CDS coverage), TSC1, TSC2, VHL.

The report

Upon conclusion of the test and analysis, we will provide a comprehensive report, summarizing the genomic information identified in our rapid 57-gene panel, the different drugs we tested and the effect of each tested drug on the tumor sample as assessed in our platform.



cResponse Report

TEST RESULTS

cResponse Score

cResponse Score

TREATMENT	SCORE
Doxorubicin	82
Alpelisib	68
Temodal+Olaparib	37
Gemzar+Docetaxel	32
Pazopanib	24
Ifosfamide	16
Palbociclib	0
Doxorubicin	82
Olaparib	45

scoring represents the response to treatment shown by the sample in EVOC. Scoring is based on morphological and histological analysis computed into a predictive algorithm. Score < 30 is considered as no response. For a detailed description of the assay refer to page 3.

Curesponse
Tel Aviv Medical Center (TAMC),
Sammy Ofer Bldg. - 10th Floor,
6 Weizmann St., Tel Aviv Yafo, Israel

2

page from 8

cResponse Report

HISTOLOGY

Pathologist: _____ / _____
(first name, last name) (signature)

TESTED DRUGS

DRUG	DATA
Palbociclib	CDK4/6 inhibitor.
Temodal	DNA methylating agent
Olaparib	PARP inhibitor
Gemzar	Nucleoside analogue, binds to DNA and inhibits its synthesis
Docetaxel	Binds tubulin and inhibits mitotic cell division
Pazopanib	Tyrosine kinase inhibitor
Ifosfamide	Alkylating agent, binds to DNA and inhibits its synthesis
Doxorubicin	Stabilizes the topoisomerase II complex, and thereby inhibits replication
Alpelisib	PI3K inhibitor

Curesponse
Tel Aviv Medical Center (TAMC),
Sammy Ofer Bldg. - 10th Floor,
6 Weizmann St., Tel Aviv Yafo, Israel

3

page from 8

support@curesponse.tech

Curesponse:
Tel aviv Medical Center (TAMC),
Sammy Ofer Bldg. - 10th Floor
6 Weizmann St., Tel Aviv Yafo | Israel

Curesponse UK Ltd:
Translation & Innovation Hub
Lab 1 19 L, Imperial College
White City Campus, 84 Wood Lane
London W12 0BZ